Evi-1 promotes para-aortic splanchnopleural hematopoiesis through up-regulation of GATA-2 and repression of TGF-β signaling

Cancer Science

Volumn 99, Issue 7, 2008, Pages 1407-1413

  Sato, Tomohiko ^a   Goyama, Susumu ^a   Nitta, Eriko ^a   Takeshita, Masataka ^a   Yoshimi, Mayumi ^a   Nakagawa, Masahiro ^a   Kawazu, Masahito ^a   Ichikawa, Motoshi ^a   Kurokawa, Mineo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RETROVIRUS VECTOR; SMAD3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EVI 1; TRANSCRIPTION FACTOR GATA 2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; ZINC FINGER PROTEIN;

ACIDITY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL STRAIN 3T3; COLONY FORMATION; CONTROLLED STUDY; DEVELOPMENTAL STAGE; EMBRYO; EMBRYO DEVELOPMENT; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TISSUE CULTURE; UPREGULATION;

ANIMALS; CELLS, CULTURED; DNA-BINDING PROTEINS; FEMALE; GATA2 TRANSCRIPTION FACTOR; HEMATOPOIESIS; MICE; MICE, INBRED C57BL; PROTO-ONCOGENES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 44449093683     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00842.x     Document Type: Article

References (34)

1. Mucenski ML, Taylor BA, Ihle JN et al. Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol 1988; 8: 301-8.
2. Ogawa S, Mitani K, Kurokawa M et al. Abnormal expression of Evi-1 gene in human leukemias. Hum Cell 1996; 9: 323-32.
3. Ogawa S, Kurokawa M, Tanaka T et al. Structurally altered Evi-1 protein generated in the 3q21q26 syndrome. Oncogene 1996; 13: 183-91.
4. Suzukawa K, Parganas E, Gajjar A et al. Identification of a breakpoint cluster region 3′ of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv (3) (q21q26). Blood 1994; 84: 2681-8.
5. Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia 1997; 11: 2022-31.
6. Buonamici S, Chakraborty S, Senyuk V, Nucifora G. The role of EVI1 in normal and leukemic cells. Blood Cells Mol Dis 2003; 31: 206-12.
7. Pintado T, Ferro MT, San Roman C, Mayayo M, Larana JG. Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer 1985; 55: 535-41.
8. Hirai H. The transcription factor Evi-1. Int J Biochem Cell Biol 1999; 31: 1367-71.
9. Buyse IM, Shao G, Huang S. The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein. Proc Natl Acad Sci USA 1995; 92: 4467-71.
10. Huang S. Blimp-1 is the murine homolog of the human transcriptional repressor PRDI-BF1. Cell 1994; 78: 9.
11. Huang S. Histone methyltransferases, diet nutrients and tumour suppressors. Nat Rev Cancer 2002; 2: 469-76.
12. Jiang GL, Huang S. The yin-yang of PR-domain family genes in tumorigenesis. Histol Histopathol 2000; 15: 109-17.
13. Lugthart S, Drunen EV, Norden YV et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: Prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008; 111: 4329-37.
14. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: A study of 319 de novo AML patients. Blood 2003; 101: 837-45.
15. Nucifora G, Laricchia-Robbio L, Senyuk V. EVI1 and hematopoietic disorders. history and perspectives. Gene 2006; 368: 1-11.
16. Kurokawa M, Mitani K, Irie K et al. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 1998; 394: 92-6.
17. Kurokawa M, Mitani K, Yamagata T et al. The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 2000; 19: 2958-68.
18. Tanaka T, Nishida J, Mitani K, Ogawa S, Yazaki Y, Hirai H. Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J Biol Chem 1994; 269: 24 020-6.
19. Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, Hirai H. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood 2001; 97: 2815-22.
20. Nitta E, Izutsu K, Yamaguchi Y et al. Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP. Oncogene 2005; 24: 6165-73.
21. Hoyt PR, Bartholomew C, Davis AJ et al. The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development. Mech Dev 1997; 65: 55-70.
22. Yuasa H, Oike Y, Iwama A et al. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 2005; 24: 1976-87.
23. Goyama S, Yamaguchi Y, Imai Y et al. The transcriptionally active form of AML1 is required for hematopoietic rescue of the AML1-deficient embryonic para-aortic splanchnopleural (P-Sp) region. Blood 2004; 104: 3558-64.
24. Nakano T, Kodama H, Honjo T. Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science 1994; 265: 1098-101.
25. Kumano K, Chiba S, Shimizu K et al. Notch1 inhibits differentiation of hematopoietic cells by sustaining GATA-2 expression. Blood 2001; 98: 3283-9.
26. Nakagawa M, Ichikawa M, Kumano K et al. AML1/Runx1 rescues Notch1-null mutation-induced deficiency of para-aortic splanchnopleural hematopoiesis. Blood 2006; 108: 3329-34.
27. Choy L, Skillington J, Derynck R. Roles of autocrine TGF-beta receptor and Smad signaling in adipocyte differentiation. J Cell Biol 2000; 149: 667-82.
28. Morita S, Kojima T, Kitamura T. Plat-E: An efficient and stable system for transient packaging of retroviruses. Gene Ther 2000; 7: 1063-6.
29. Kurokawa M, Tanaka T, Tanaka K et al. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies. Oncogene 1996; 12: 883-92.
30. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 2000; 96: 2022-36.
31. Kano MR, Bae Y, Iwata C et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-[beta] signaling. Proc Natl Acad Sci USA 2007; 104: 3460-65.
32. Sitnicka E, Ruscetti FW, Priestley GV, Wolf NS, Bartelmez SH. Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopulating hematopoietic stem cells. Blood 1996; 88: 82-8.
33. Towatari M, May GE, Marais R et al. Regulation of GATA-2 phosphorylation by mitogen-activated protein kinase and interleukin-3. J Biol Chem 1995; 270: 4101-7.
34. Hayakawa F, Towatari M, Ozawa Y, Tomita A, Privalsky ML, Saito H. Functional regulation of GATA-2 by acetylation. J Leukoc Biol 2004; 75: 529-40.